Proprietary

A dynamic transmission model for assessing the impact of pneumococcal vaccination

Tufail M Malik[1*], Kevin M Bakker[1], Rachel J Oidtman[1], Oluwaseun Sharomi[1], Giulio Meleleo[2], Robert Nachbar[2], Elamin H Elbasha[1]

[1]Merck & Co., Inc., Rahway, NJ, USA

[2]Wolfram Research, Inc., Champaign, IL, USA

Abstract

Streptococcus pneumoniae (SP) is a bacterial pathogen that kills more than 300,000 children every year across the globe. Multiple vaccines exist that prevent pneumococcal disease, with each vaccine covering a variable number of the more than 100 known serotypes. Due to the high effectiveness of these vaccines, each new pneumococcal conjugate vaccine (PCV) introduction has resulted in a decrease in vaccine-type disease and a shift in the serotype distribution towards non-vaccine types in a phenomenon called serotype replacement. Here, an age-structured compartmental model was created to capture the carriage transmission dynamics of SP and subsequent progression to pneumococcal disease in the presence of vaccines introduced at different times to different age groups. The model incorporates co-colonization and serotype

* tufail.malik@merck.com

competition, which drives replacement of the vaccine types by the non-vaccine types. The model was calibrated to historical age- and serotype-specific invasive pneumococcal disease (IPD) data from the United States using vaccine-specific coverage and effectiveness. The calibrated model was then used to project the epidemiological impact of PCV15, a 15-valent pneumococcal vaccine, compared with the status quo vaccination with PCV13 and demonstrated the value of added serotypes in PCV15. Projections revealed that PCV15 would reduce IPD incidence by 6.04% (range: 6.01% to 6.06%) over 10 years when compared to PCV13.

Introduction

Despite the widespread use of pneumococcal vaccines in the United States (US), *Streptococcus pneumoniae* (SP) caused nearly 17,400 cases of invasive pneumococcal disease (IPD) in 2021, and nearly 3,000 associated deaths [1]. Globally the number of deaths in children under 5 is approximately 300,000 [2]. Vaccines are only able to target a portion of the more than 100 circulating serotypes (STs) [3], and serotype-specific vaccine effectiveness has been observed. Only a small fraction of these cause majority of disease. Asymptomatic or symptomatic nasopharyngeal carriage (NPC) of SP in an individual, which is relatively common in young children [4], may result in SP transmission to other individuals through person-to-person contact via respiratory droplets. NPC can lead to multiple disease outcomes, including invasive pneumococcal disease (IPD), non-bacteremic pneumococcal pneumonia (NBPP), and acute otitis media (AOM) [5]. IPD, which includes meningitis and bacteremic pneumonia, primarily afflicts extremes of ages and those with risk factors [6]. Vaccines play a role in preventing NPC but the necessary immune response is higher than what is required to prevent disease.

In the US a pediatric vaccination program with a 7-valent pneumococcal conjugate vaccine (PCV) was introduced in 2000, and building on this composition, a 13-valent PCV was introduced in 2010, followed by a 15-valent vaccine in 2022, and a 20-valent vaccine in 2023. Since 1983, a 23-valent pneumococcal polysaccharide vaccine (PPSV23) had been recommended for all adults 65 years or older. Vaccines targeting additional or different serotypes, along with those based on other technologies, are currently in development. Since the introduction of PCVs, the US has seen a dramatic reduction in IPD across all age groups in vaccine-type (VT) serotypes [6]. There has also been replacement of VTs with non-vaccine types (NVTs) [7]. Globally, there have been higher levels of replacement than those seen in the US, sometimes leading to higher overall incidence levels than the pre-vaccine period (for example in France following PCV13 introduction [8]).

Dynamic transmission models (DTMs) have been used extensively to describe the epidemiological and biological dynamics of SP transmission in the presence or absence of vaccination (Table S1 summarizes a review of published models). Here, a DTM was developed to quantify the epidemiological impact of ST-specific and age-based vaccination programs. The model is driven by carriage transmission and assigns each ST into one of 11 serotype classes (STCs, Table S7), which were determined based on their inclusion in different pneumococcal vaccines. Additionally, the model features indirect effects such as herd immunity and competition between ST classes, which determines replacement dynamics following vaccine introduction. The model is flexible, so that it can be used in countries that report disease incidence with different age-groups, incorporated different vaccines into their vaccine schedules (e.g., PCV10), want to examine different vaccination policies, or are interested in other pneumococcal diseases of interest. The model was fitted to historical (2000–2019) US IPD data

and the epidemiological impact of the continued use of PCV13 versus implementing PCV15 in the pediatric immunization program was assessed (at the time of this study PCV20 was not yet recommended in peds in the US).

Methods

A model was developed that described SP carriage transmission dynamics and disease progression in the presence of age- and serotype-specific pneumococcal vaccines. Real-world data was used to inform parameters for vaccine effectiveness against disease, coverage rates, duration of protection, carriage clearance rates, and a mixing within and between age groups. Real-world data are lacking for PCV15 given recent introduction. Population data was used to parameterize the demographic aspects of the model.

The model was calibrated to national-level IPD data in the US to estimate the probability of SP carriage acquisition per contact, competition between STCs, progression rate from carriage to disease, and vaccine effectiveness against carriage. Disease incidence data were stratified by age and grouped into STCs, based on inclusion in various vaccines (Table S7). With the calibrated model, epidemiological projections were made under different pediatric vaccination scenarios keeping a realistic mix of vaccination regime in the adult population.

Model overview

A deterministic age-structured DTM was constructed to describe pneumococcal carriage transmission dynamics and disease progression in the presence of age- and STC-specific pneumococcal vaccines. In addition to the brief description of the model here, additional details can be found in the Supplementary Appendix. Given the lack of data to parameterize the model

for all serotypes and disease outcomes, it was assumed that parameter values were constant across serotypes within the same STC and age group. Each STC was further categorized into 6 age groups (0–1, 2–4, 5–17, 18–49, 50–64, and 65+). The model was based on a system of ordinary differential equations and distinguished pneumococcal carriage from disease as well as their vaccine protection status, which varied by age and vaccine type (Fig 1). For example, an unvaccinated person can be either susceptible non-colonized or colonized with up to three STCs. A fraction of infants are born into the unvaccinated susceptible non-colonized compartment and remain there until they are vaccinated, become colonized, or die from causes other than pneumococcal disease. Individuals acquire one or two STCs simultaneously at an age-specific and time-dependent rate (i.e., per capita force of carriage acquisition), progressing from non-colonized status to single or double colonization, from single to double or triple colonization, and from double to triple colonization. It was assumed that an individual could be colonized by up to three STCs concurrently.

Fig 1. Model flowchart. Individuals are born into the non-colonized compartments and can move throughout the system during their lifetime. Upon carriage acquisition, individuals move to the colonized (with a single ST), co-colonized with two STs, or triple-colonized compartments. Colonized individuals can clear carriage of one ST at a time. A proportion of colonized individuals will develop a pneumococcal disease. Vaccination (right arm of flowchart) reduces the chance of carriage acquisition and disease development for vaccine STCs. Detailed model flowchart is provided in Figures S3, S4 and S5.

The rate at which uncolonized persons of a given age group acquire SP and become colonized depends on the number and type of contacts, the fraction of colonized, co-colonized, and tri-colonized contacts, and the transmission probability per contact, which varies by age. The number and type of contacts are governed by a conditional probability mixing matrix, where each cell represents the probability of a person of a given age class having contact with a person

in another age class (Table S4). Upon recovery, it is assumed that the person does not develop immunity and becomes completely susceptible again.

Individuals leave the unvaccinated compartments through cohort and continuous vaccination at given rates and enter the appropriate vaccinated compartment, based on their colonization status. They remain in the vaccinated compartments until they die, acquire SP, or their immunity wanes. Since typical colonization is asymptomatic, individuals can be vaccinated from any of the four (uncolonized, colonized, double colonized, or triple-colonized) unvaccinated compartments. Vaccination reduces the risk of carriage acquisition and disease progression.

In the DTM, the rate of acquisition of a second or third STC is reduced due to competition from the currently carried STC(s). The competition parameter is determined by the relationship between the current and the invading STC, and can range from zero competition (i.e., independence) to complete competition (i.e., exclusion), where the acquisition of the invading STC is completely blocked by the currently carried STC(s).

Disease occurrence was modeled using a case-carrier ratio that varies by disease manifestation, age, STC, and vaccine-status. Progression to IPD, AOM, or NBPP were included here, while other manifestations (such as sinusitis) or further classification (such as bacteremia) could be included in future analyses.

In addition to the scenarios evaluated here, the model is flexible and can evaluate other vaccine scenarios, such as reducing the vaccination age in adults, having sequential vaccination of different vaccines in an age group, other vaccines, or other potential policy questions.

Model parameters and data sources

Baseline values for demographic, epidemiologic, and vaccine inputs of the model were identified through a targeted search of the published literature and public databases.

Demographic parameters

A stable equilibrium age distribution (with 2017 as the baseline year) and constant mortality hazards for each age group were assumed, using data from the US Census Bureau website (https://www.census.gov/). Since the implied growth rate was insignificant, constant population was assumed over the analysis time horizon to reduce model complexity.

Contact mixing matrix

Mixing patterns among the population impact the transmission dynamics of an infectious pathogen. Mixing patterns from Prem *et al*. [9] were derived to create the 6-age group contact matrix (see Section 3.1.3 of the Supplementary Appendix). Although transmission among adults was allowed, it was assumed that there was no transmission of SP from adults to the pediatric population [10].

Vaccine parameters

The model assumed full vaccine compliance (i.e., 3+1 doses in pediatric population) and used the respective age-specific observed vaccine coverage rates (VCRs) over the historical period and anticipated VCRs for projections. VCR in each vaccine-target age group is discussed in Supplementary Appendix. In the model, a distinction between two types of vaccine effectiveness (VE) was made: VEc against carriage acquisition and VEd against pneumococcal disease (VEd was unique for each disease outcome of IPD, AOM, and NBPP). VEs vary by vaccine (PCV13, PCV15, PCV20, and PPSV23), STC, and age group. VEds against NBPP and AOM can be seen in Supplementary Tables S10 and S11. VEcs were calibrated in the model.

STC- and age-specific VEds against IPD of all vaccines considered in the model were based on clinical trials and real-world-evidence studies (Table 1). VEd of PCV13 against STC1-type (i.e., PCV7 STs) IPD in children was assumed to be identical to published PCV7 VEd [11]. ST-specific VEds for the additional PCV13 serotypes were taken from Moore *et al.* [12]. Since VEds within an STC may vary, VEds for each STC in children were estimated as the incidence-weighted average of individual VEds. There is no consensus regarding the VEd of PCV13 on serotype 3 [13]. Despite high pediatric coverage levels, real world evidence reveals that the long-term impact of PCV13 has had little to no effect on population-level ST3 incidence. Therefore, VEd against ST3 in the base case was assumed to be equal to the left end point of the 95% confidence interval from Moore *et al*. [12].

Table 1. Vaccine effectiveness against IPD by age and serotype class. (PCV20 was only considered for adult vaccination).

		Age (years)			
	STC	**0-17**	**18-49**	**50-64**	**65+**
PCV13	**1**	0.96	0.739	0.713	0.677
	2	0.87	0.739	0.713	0.677
	3	0.303*	0.256	0.247	0.235
	4	0.883	0.739	0.713	0.677
	5	0.86	0.739	0.713	0.677
	6-11	0			
PCV15	**1-5**	Identical to PCV13 VE			
	6	0.86	0.739	0.713	0.677
	7-11	0			
PCV20	**1-6**	Identical to PCV15 VE			
	7	0			
	8, 9	NA	0.739	0.713	0.677
	10, 11	0			
PPSV23	**1-4, 6-9**	NA	0.585	0.559	0.521
	5,10,11	NA	0	0	0

IPD: Invasive Pneumococcal Disease; STC: Serotype Class; NA: Not Applicable;

PCV13: 13-valent pneumococcal conjugate vaccine; PCV15: 15-valent pneumococcal conjugate vaccine; PCV20: 20-valent pneumococcal conjugate vaccine; PPSV23: 23-valent pneumococcal polysaccharide vaccine; ST3 = serotype 3; STCs = serotype classes;

*: left end point of 95%CI.

Populations in each adult age group include those at low risk for pneumococcal disease (healthy individuals) as well as those with increased risk due to immunocompromising conditions. The VEd of PCV13 for IPD in adults who are at-risk was based on Bonten *et al*. [14] and Leidner *et al*. [15], and VEd of PPSV23 was based on [15]. These were incorporated into the age-based population-level VEds based on risk distribution by age (Table S9).

Equivalency was assumed for the new vaccines, which is that new PCVs with additional STs (e.g PCV15 and PCV20) have equivalent VEds as previous PCVs (PCV13) for shared serotypes. Overall VEd of PCV13 [12] was used as VEd of PCV15 against STC6-type IPD in children. PCV13 VEd in adults was not ST-specific and was extended to additional PCV15 and PCV20 STCs (Table 1).

In a scenario analysis STC-specific VEd for PCV15 was based on immune response of PCV15 relative to PCV13. Results of this scenario analysis are presented in the Supplementary Appendix.

It was assumed that mean duration of protection from any PCV was 10 years, while PPSV23 was assumed to have a mean duration of protection of 7.5 years [15].

Carriage clearance rates

Annual carriage clearance rates for a given serotype were calculated as the inverse of carriage duration. A literature review was performed to collect data on age and serotype-specific carriage durations. For each age-STC combination the total carriage duration across studies was divided by the total population across studies and normalized by age group. More details on these derivations are available in Section 3.2.4.1.1 of the Supplementary Appendix.

Model calibration

To infer the values of the age- and STC-specific probability of acquisition, age- and STC-specific case-carrier ratios, STC-specific competition parameters, and the STC-specific VEc for the VTs, the model was calibrated to historical US IPD incidence data from 2000–2019. Pneumococcal dynamics were impacted from the COVID-19 pandemic [16] through reduced transmission due to non-pharmaceutical interventions and disruption of routine healthcare services including vaccination. Since the model does not account for such dynamics, data after 2019 was not included in model calibration. Calibration methodology and detailed results are described further in the Supplementary Appendix.

Calibration target

Age-stratified STC-specific IPD incidence per 100,000 in the US from 1998-2019 was used as calibration target. These incidence data were generated by Merck & Co., Inc., Rahway, NJ, USA using serotype distribution data from Active Bacterial Core surveillance (ABCs), Centers for Disease Control and Prevention (CDC), and the annual IPD incidence from the annual CDC surveillance reports [17] and may differ from data published by the CDC.

For calibration to NBPP data, pediatric NBPP incidence per 100,000 from 1998–2018 was obtained from Hu *et al*. [18]. To obtain the counterpart data in adults, all-cause pneumonia (ACP) incidence was acquired from Truven MarketScan Commercial Claims and Encounters (January 1, 2012 to December 2020). It was assumed that 11% of ACP had pneumococcal etiology—NBPP—in US adults [19]. For pediatrics, it was assumed that ST distribution for NBPP followed that of IPD. For adults, the proportion of NBPP attributable to STCs was calculated using data from two recent studies [20, 21] and the STC- and age-specific data was constructed (see Section 5.1 of Supplementary Appendix for additional details).

For AOM calibration, pediatric all-cause AOM incidence per 100,000 from 1998-2018 was obtained from Hu *et al*. [22] of which 23.8% was pneumococcal attributable [23]. Studies with ST distribution information for AOM cases [23, 24, 25] were used to construct the STC- and age-specific data (see Section 5.2 in Supplementary Appendix for additional details).

Using the carriage prevalence profile that corresponded to calibrated IPD incidence, case-carrier ratios for NBPP and AOM were then calibrated using the historical incidence of each manifestation. Details on NBPP and AOM calibration, procedure, and results are provided in the Supplementary Appendix.

Model projections

The calibrated model was then used to compare pneumococcal disease burden assuming either pediatric PCV13 or PCV15 vaccination. In adults, both PCV15 with PPSV23 or PCV20 have been recommended for use [26]. A hypothetical combination of these vaccines was constructed. In addition, given the historic practice, we assumed that healthcare providers may continue to administer PPSV23 alone. Therefore, to design an adult vaccination scenario (which would be kept same while comparing the two pediatric vaccination scenarios) it was assumed that of the vaccinated US adults 80% receive PCV20, 10% receive PCV15+PPSV23, and 10% receive PPSV23 alone. Since adult vaccination was identical between these two scenarios, the differences in model outcomes were solely caused by pediatric vaccination.

The two scenarios are summarized below:

1. Scenario PCV13: Children 0-2 receive PCV13 according to assumed VCR. Given assumed VCR among adults 18+, 80% receive PCV20, 10% receive PPSV23, and 10% receive PCV15+PPSV23.

2. Scenario PCV15: Children 0-2 receive PCV15 according to assumed VCR. Given assumed vaccination coverage among adults 18+, 80% receive PCV20, 10% receive PPSV23, and 10% receive PCV15+PPSV23.

Results

IPD data calibration results

The model was able to capture historical trends in each of the STCs for each age group (Fig 2, 3). Before the introduction of a PCV in the US, PCV7 serotypes (STC1) dominated the IPD landscape. However, after the introduction of PCV7 in 2000 and prior to the introduction of PCV13 in 2010, replacement occurred, with the additional PCV13 (excluding ST3) serotypes increasing in incidence. This replacement behavior was captured by the model due to the inclusion of a competition parameter. In 2010 PCV13 was introduced and all PCV13 STCs, other than ST3, declined. ST3, both in the model and data, remained relatively constant across the calibration period. Following PCV13 introduction, all non-vaccine STCs trended upward.

Prior to PCV7, STC1 outcompeted other STs, but following PCV7 introduction, and the reduction in STC1 STs, STCs 4,7, &10 were able to spread due to the reduced competitive pressure from STC1 STs

Fig 2. Calibrated versus IPD incidence per 100,000 over time in children age groups. Dashed lines: data; Solid lines: model outcome.

Fig 3. Calibrated versus IPD incidence per 100,000 over time in adult age groups. Dashed lines: data; Solid lines: model outcome.

IPD = invasive pneumococcal disease; PCV7 = 7-valent pneumococcal conjugate vaccine; PCV13 = 13-valent pneumococcal conjugate vaccine; PCV15 = 15-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent pneumococcal polysaccharide vaccine; ST3 = serotype 3; STCs = serotype classes; V116 = an investigational 21-valent pneumococcal conjugate vaccine.

Years of real-world data following the introduction of new vaccines will be necessary to estimate how new vaccine type STs, such as 22F and 33F (STC6) compete and interact with other STCs.

The model estimated age- and serotype-specific VEc, which revealed PCV7 to have a greater impact against the 7 serotypes it targeted than PCV13 had on the additional 6 serotypes it targeted (Table S18). The model also calculated age- and serotype-specific case-to-carrier ratios for IPD (Table S17). Results indicated that these case-carrier ratios were highest in the youngest and oldest age groups.

Following the calibration of the model to IPD incidence, which generated age- and STC-specific carriage acquisition rates, the model was then calibrated to estimate the age- and STC-specific case-carrier ratios for each of AOM and NBPP. The model captured changes in the serotype distribution associated with AOM after different vaccine introductions, such as the decline of 5 of the additional serotypes included in PCV13 (excluding STC3) (Figure S14). Similarly, the model replicated reductions in PCV7 STs in 2000 and STC4 (7F, 19A) in 2010 in pediatric NBPP following the introduction of PCV7 and PCV13 (Figure S13).

Epidemiological projections

The calibrated model was used to make projections for the two scenarios described above (Fig 4). Projections revealed that PCV15 prevented more cases of IPD, AOM, and NBPP than PCV13 across all age groups. The reduced incidence of IPD in pediatric age groups under the PCV15 scenario reflected the direct and indirect benefit due to the added vaccine type serotypes 22F and

33F, while the lower incidence in adult age groups was due to indirect protection (i.e., herd immunity) from the pediatric population. It was estimated that over 10 years, PCV15 would reduce about 6% more cases of IPD when compared to PCV13. This includes around 12.76% more cases averted in children under 2 and 4.82% more cases averted in adults over the age of 65.

Fig 4. IPD incidence per 100,000 projected by the calibrated model. Top: IPD burden, children < 5; Bottom: Overall IPD burden by age group. Vaccination in adults: 80% receive PCV20, 10% receive PPSV23, and 10% receive PCV15+PPSV23. Vaccine coverage used in these projections is given by Figure S6. Reduced IPD incidence in adults is a result of indirect protection of pediatric PCV15 vaccination.

IPD = invasive pneumococcal disease; PCV13 = 13-valent pneumococcal conjugate vaccine; PCV15 = 15-valent pneumococcal; STs = serotypes; VE = vaccine effectiveness

The model estimated that after 10 years, compared to PCV13, PCV15 will also reduce the number of NBPP cases by 5.5% and the number of AOM cases by about 3%.

Projected IPD STC distribution

Fig 5 shows the pre-PCV, 2019, and 10 year-projections of IPD incidence. By 2019, PCV7 and PCV13 reduced overall IPD, however ST-distributions shifted with NVTs replacing VTs over this same period. The third column shows the projected shift in this distribution following 10 years of PCV15 utilization. STs 22F and 33F (PCV15 non-PCV13) are diminished with PCV15. There is a clear shift from vaccine-types towards NVTs (Other STs) through ST replacement. Since PCV20 was implemented in adult age groups (18 and above) in projection period, IPD in the PCV20 non-PCV15 STC was reduced in adults.

Fig 5. IPD incidence (cases per 100,000) attributed to each STC grouped by vaccine in each model age group. Model calibrated STC distributions and data at the start and end of calibration period (2000 and 2019 respectively), and model projected STC distributions after 10 years of PCV15 in children.

IPD = invasive pneumococcal disease; PCV7 = 7-valent pneumococcal conjugate vaccine; PCV13 = 13-valent pneumococcal conjugate vaccine; PCV15 = 15-valent pneumococcal conjugate vaccine; PPSV23 = 23-valent pneumococcal polysaccharide vaccine; ST3 = serotype 3; STCs = serotype classes

Discussion

An age-structured dynamic model of pneumococcal carriage transmission was developed to evaluate the epidemiological impact of age-based vaccine policies on pneumococcal diseases. Serotypes were divided into serotype classes (STCs) which allowed disease incidence to be examined by each age and STC combination.

The model was calibrated to the historical age-specific US IPD incidence data from 2000 to 2019 and used to project future outcomes under different vaccine strategies. The results of this calibration revealed age- and serotype-specific carriage acquisition probabilities, competition parameters between STCs, age- and serotype-specific vaccine efficacies against carriage, and age- and serotype specific case-to-carrier ratios for invasive and non-invasive pneumococcal disease (IPD, NBPP, and AOM). Calibrated values fell within the range of published estimates where available or were aligned with calibration estimates of published models.

Probability of carriage acquisition per contact with a colonized individual, which is an age- and STC-specific parameter, was highest in the youngest and oldest age groups due to weak immune systems (i.e., immature in children [27] and deficient due to age in older adults [28]). This implies that children in the first two age groups (aged 0-4) and individuals in the oldest age group (aged 65+) are most likely to acquire carriage upon contact with a colonized individual of any age. These results are consistent with other literature (for example, see [29, 30, 31]). Case-to-carrier ratios for IPD followed a similar pattern, with those in the youngest and oldest age

groups most likely to develop disease from carriage acquisition [32]. Calibration estimates of case-to-carrier ratios for IPD also fall within the range of published estimates [32, 33, 34, 35]. The calibrated competition parameter estimates correctly reflected the ST replacement in the US whereby NVTs increased to fill the niche that arose due to target STs declining following PCV7 and PCV13 implementation. Modeling literature highlights the role of ST competition [36] and some pneumococcal transmission models have included this feature at a higher level or in some aggregation [37, 38, 39]. However, calibrated ST competition between PCV7 STs against non-PCV7 STs, and PCV13 STs against non-PCV13 STs, to our knowledge, has not been examined at such granularity before.

Our parameter estimates of STC-specific VEc aligned with those reported in published literature [40, 41]. Like pneumococcal disease, PCVs are also less protective against ST3 acquisition [42]. This is evident from the relatively low calibrated VEc against ST3 which was also the case with other published model calibrations that reported ST-specific VEc [29]. Additionally, VEc in adults is lower than the respective STC-specific VEc in children. Since carriage acquisition is a precursor for pneumococcal disease, protection against acquisition is the first level of defense that PCVs offer; reduction in acquisition will lead to reduction in disease.

Since dynamic transmission models estimate the time-dependent dynamics of population-level susceptibility along with factors that affect the transmission rate (e.g., vaccination status and carriage acquisition in response to mixing patterns), they are well suited to provide insights into the indirect protection provided from interventions, such as including vaccination. Our model assumes no transmission from adults to children [10] so there is no indirect effect of vaccinating adults on children. Indirect protection of pediatric vaccination on adults which has been observed in programs where pneumococcal vaccines have been implemented in pediatric programs [43],

can be analyzed in detail using this model. Here, identical vaccination strategies in adults were kept and the two different vaccination programs in children, PCV13 versus PCV15, were compared. Due to indirect protection (i.e., herd immunity), the implementation of PCV15 in pediatrics led to additional reductions in adult disease attributed to 22F and 33F.

The model does have some limitations. First, because of lack of data to estimate some parameters such as STC-specific probability of SP acquisition we inferred the values of some of these parameters by calibrating the model outcomes to historical data. Second, certain serotypes, such as serotype 3, have evolved under pressure from vaccination [44, 45] but the model does not account for such evolution, assuming the same properties of STCs throughout the calibration and projection horizons. It is also worth highlighting that including several STs into a single STC entails strong assumption that STs in the same STC have identical properties.

The flexibility and accuracy of the model demonstrates promise for future adaptions in other settings, where local pneumococcal epidemiology may vary, such as different age-reporting, vaccine history, vaccine dosing, vaccine efficacies, different STs of interest, or different policy questions. The model implemented here focused on epidemiological outcomes, but in future work the model could additionally be used to evaluate the cost-effectiveness of different vaccines or vaccination strategies. Understanding that certain viral pathogens, such as respiratory syncytial virus, influenza, and human metapneumovirus may facilitate IPD [46, 47, 48, 49], historical data from these pathogens can also be included into the model to capture some of the unexplained inter-annual variation in IPD incidence.

Funding: This study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Conflicts of Interest: Tufail M Malik, Kevin M Bakker, Rachel J Oidtman, Oluwaseun Sharomi and Elamin H Elbasha are employees and stockholders of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

References

[1] "Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae," Centers for Disease Control and Prevention, 1998-2021. [Cited 2024 Apr 17]. Available: https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2021.pdf.

[2] Wahl B, O'Brien KL, Greenbaum A, Majumder A, Liu L, Chu Y, Lukšić I, Nair H, McAllister DA, Campbell H, Rudan I, Black R and Knoll MD, "Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000-15," *Lancet Glob Health,* vol. 6, pp. e744-e757, 2018.

[3] Hausdorff W, Feikin D and Klugman K, "Epidemiological differences among pneumococcal serotypes," *Lancet Infect Dis,* vol. 5, pp. 83-93, 2005.

[4] Jagne I, von Mollendorf C, Wee-Hee A, Ortika B, Satzke C and Russell F, "A systematic review of pneumococcal conjugate vaccine impact on pneumococcal nasopharyngeal colonisation density in children under 5 years of age," *Vaccine,* vol. 41, pp. 3028-37, 2023.

[5] Simell B, Auranen K, Kayhty H, Goldblatt D, Dagan R, O'Brien K and PneumoCarr, "The fundamental link between pneumococcal carriage and disease," *Expert Rev Vaccines,* vol. 11, pp. 841-55, 2012.

[6] Gierke R, Wodi AP and Kobayashi M, "Epidemiology and Prevention of Vaccine-Preventable Diseases," Centers for Disease Control and Prevention, 18 August 2021. [Cited 2024 Apr 17]. Available: https://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html.

[7] Weinberger DM, Malley R and Lispitch M, "Serotype replacement in disease after pneumococcal vaccination," *Lancet,* vol. 6736, no. 10, pp. 1962-73, 2011.

[8] Ouldali N, Varon E, Levy C, Angoulvant F, Georges S, Ploy M-C, Kempf M and Cremniter J, "Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study," *Lancet Infect Dis,* vol. 21, pp. 137-47, 2021.

[9] Prem K, Cook A and Jit M, "Projecting social contact matrices in 152 countries using contact surveys and demographic data," *PLoS Comput Biol,* vol. 13, 2017.

[10] Althouse B, Hammitt L, Grant L, Wagner B, Reid R, Larzelere-Hinton F, Weatherholtz R, Klugman K, Rodgers G and O'Brien K, "Identifying transmission routes of Streptococcus pneumoniae and sources of acquisitions in high transmission communities," *Epidemiol Infect,* vol. 145, no. 13, pp. 2750-8, 2017.

[11] Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist A-C, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP and Zell ER, "Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study," *Lancet,* vol. 368, no. 9546, pp. 1495-502, 2006.

[12] Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, Zansky SM, Rosen JB, Reingold A, Scherzinger K, Thomas A, Guevara RE and Motala T, "Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study," *Lancet Respir Med,* vol. 4, no. 5, pp. 399-406, 2016.

[13] T Pilishvili, "13-valent pneumococcal conugate vaccine (PCV13) effects on disease caused by serotype 3 (Advisory Committee on Immunization Practices)," 28 February 2019. [Cited 2024 Apr 17]. Available: https://stacks.cdc.gov/view/cdc/78091.

[14] Bonten MJM, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. "Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults," *N Engl J Med,* vol. 372, no. 12, pp. 1114-25, 2015.

[15] Leidner A, "Summary of three economic models assessing pneumococcal vaccines in US adults (ACIP Presentation Slides: September 29, 2021 Meeting)," 2021. [Cited 2024 Apr 17]. Available: https://www.cdc.gov/vaccines/acip/meetings/slides-2021-09-29.html.

[16] Dagan R, Danino D and Weinberger D, "The Pneumococcus-Respiratory Virus Connection-Unexpected Lessons From the COVID-19 Pandemic," *JAMA Netw Open,* vol. 5, 2022.

[17] "Centers for Disease Control and Prevention," Active Bacterial Core surveillance. [Cited 2024 Apr 17]. Avaliable: https://www.cdc.gov/abcs/reports-findings/surv-reports.html.

[18] Hu T, Sarpong EM, Song Y, Done N, Liu Q, Lemus-Wirtz E, Signorovitch J, Mohanty S and Weiss T, "Incidence of non-invasive all-cause pneumonia in children in the United States before and after the introduction of pneumococcal conjugate vaccines: a retrospective claims database analysis," *Pneumonia (Nathan),* vol. 15, no. 1, 2023.

[19] Choi MJ, Song JY, Cheong HJ, Jeon JH, Kang SH, Jung EJ, Noh JY and Kim WJ, "Clinical usefulness of pneumococcal urinary antigen test, stratified by disease severity and serotypes," *J Infect Chemother,* vol. 21, no. 9, pp. 672-9, 2015.

[20] Isturiz R, Grant L and Gray S, "Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults," *Clin Infect Dis,* vol. 73, no. 7, pp. 1216-22, 2021.

[21] Isturiz RE, Ramirez J, Self WH, Grijalva CG, Counselman FL, Volturo G, Ostrosky-Zeichner L, Peyrani P, Wunderink RG, Sherwin R, Overcash JS, Oliva SP and File T, "Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia," *Vaccine,* vol. 37, no. 25, pp. 3352-61, 2019.

[22] Hu T, Done N, Petigara T, Mohanty S, Song Y, Liu Q, Lemus-Wirtz E, Signorovitch J, Sarpong E andWeiss T, "Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018," *BMC Infec Dis,* vol. 22, no. 1, 2022.

[23] Kaur R, Fuji N and Pichichero ME, "Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015-2019," *Eur J Clin Microbiol Infect Dis,* vol. 41, no. 1, pp. 37-44, 2022.

[24] Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R and Keegan E, "Pneumococcal serotypes from acute otitis media in rural Kentucky," *Pediatr Infect Dis J,* vol. 21, no. 9, pp. 859-65, 2002.

[25] Casey JR, Adlowitz DG and Pichichero ME, "New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine," *Pediatr Infect Dis J,* vol. 29, no. 4, pp. 304-9, 2010.

[26] Kobayashi M, Farrar JL, Gierke R, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Poehling KA and Cohen AL, "Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022," *MMWR,* vol. 71, pp. 1174-81, 2022.

[27] Lambert L and Culley F, "Innate Immunity to Respiratory Infection in Early Life," *Front Immunol,* vol. 8, 2017.

[28] Krone C, van-de-Groep K, Trzcinski K, Sanders E and Bogaert D, "Immunosenescence and pneumococcal disease: an imbalance in host-pathogen interactions," *Lancet Respir Med,* vol. 2, pp. 141-53, 2014.

[29] Wasserman M, Lucas A, Jones D, Wilson M, Hilton B, Vyse A, Madhava H, Brogan A, Slack M and Farkouh R, "Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK," *Epidemiol Infect,* vol. 146, no. 14, pp. 1797-806, 2018.

[30] Mosser JF, Grant LR, Millar EV, Weatherholtz RC, Jackson DM, Beall B, Craig MJ, Reid R, Santosham M andO'Brien KL, "Nasopharyngeal carriage and transmission of Streptococcus pneumoniae in American Indian households after a decade of pneumococcal conjugate vaccine use," *PLoS One,* vol. 9, 2014.

[31] Melegaro A, Gay N and Medley G, "Estimating the transmission parameters of pneumococcal carriage in households," *Epidemiol Infect,* vol. 132, pp. 433-41, 2004.

[32] Choi Y, Jit M, Flasche S, Gay N and Miller E, "Mathematical modelling long-term effects of replacing Prevnar7 with Prevnar13 on invasive pneumococcal diseases in England and Wales," *PLoS One.,* vol.

7, no. 7, p. e39927, 2012.

[33] Southern J, Andrews N, Sandu P, Sheppard CL, Waight PA, Fry NK, Van Hoek AJ and Miller E, "Pneumococcal carriage in children and their household contacts six years after introduction of the 13-valent pneumococcal conjugate vaccine in England," *PLoS One,* vol. 13, 2018.

[34] Yildirim I, Little B, Finkelstein J, Lee G, Hanage W, Shea K and Pelton S, "Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts' children to relatively low invasiveness," *Vaccine,* vol. 35, pp. 4002-9, 2017.

[35] Lochen A and Anderson R, "Dynamic transmission models and economic evaluations of pneumococcal conjugate vaccines: a quality appraisal and limitations," *Clin Microbiol Infect,* vol. 26, no. 1, pp. 60-70, 2020.

[36] Lipsitch M, "Vaccination against colonizing bacteria with multiple serotypes," *Proc Natl Acad Sci U.S.A.,* vol. 94, no. 12, pp. 6571-6, 1997.

[37] Melegaro A, Choi Y, George R, Edmunds W, Miller E and Gay N, "Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease," *BMC Infect Dis,* vol. 90, p. 10, 2010.

[38] Masala G, Lipsitch M, Bottomley C and Flasche S, "Exploring the role of competition induced by non-vaccine serotypes for herd protection following pneumococcal vaccination," *J R Soc Interface,* vol. 14, no. 136, 2017.

[39] De-Cao E, Melegaro A, Klok R and Postma M, "Optimising assessments of the epidemiological impact in The Netherlands of paediatric immunisation with 13-valent pneumococcal conjugate vaccine using dynamic transmission modelling," *PLoS One,* vol. 9, no. 4, p. e89415., 2014.

[40] Gjini E, "Geographic variation in pneumococcal vaccine efficacy estimated from dynamic modeling of epidemiological data post-PCV7," *Sci Rep,* vol. 7, no. 1, p. 3049, 2017.

[41] Rinta-Kokko H, Dagan R, Givon-Lavi N and Auranen K, "Estimation of vaccine efficacy against acquisition of pneumococcal carriage," *Vaccine,* vol. 27, no. 29, pp. 3831-7, 2009.

[42] Lapidot R, Shea K, Yildirim I, Cabral H, Pelton S and The Massachusetts Department of Public Health, "Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts," *Pathogens,* vol. 9, 2020.

[43] Miller E, Andrews N, Waight P, Slack M and George R, "Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study," *Lancet Infect Dis,* vol. 11, pp. 760-8, 2011.

[44] Groves N, Sheppard CL, Litt D, Rose S, Njoku ASN, Rodrigues S, Amin-Chowdhury Z, Andrews N, Ladhani S and Fry NK, "Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A

Major Vaccine Evader," *Genes (Basel),* vol. 10, 2019.

[45] Azarian T, Mitchell PK, Georgieva M, Thompson CM, Ghouila A, Pollard AJ, et al., "Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci," *PLoS Pathog,* vol. 14, 2018.

[46] Ben-Shimol S, Greenberg D, Hazan G, Shemer-Avni Y, Givon-Lavi N and Dagan R, "Seasonality of both bacteremic and nonbacteremic pneumonia coincides with viral lower respiratory tract infections in early childhood, in contrast to nonpneumonia invasive pneumococcal disease, in the pre-pneumococcal conjugate vaccine era," *Clin Infect Dis,* vol. 60, no. 9, pp. 1984-7, 2015.

[47] Weinberger DM, Grant LR, Steiner CA, Weatherholtz R, Santosham M, Viboud C and O'Brien KL, "Seasonal Drivers of Pneumococcal Disease Incidence: Impact of Bacterial Carriage and Viral Activity," *CID,* vol. 584, 2014.

[48] Weinberger DM, Harboe ZB, Viboud C, Krause TG, Miller M, Mølbak K and Konradsen HB, "Serotype-specific effect of influenza on adult invasive pneumococcal pneumonia," *J Infect Dis,* vol. 208, no. 8, pp. 1274-80, 2013.

[49] Stensballe LG, Hjuler T, Andersen A, Kaltoft M, Ravn H, Aaby P and Simoes EAF, "Hospitalization for respiratory syncytial virus infection and invasive pneumococcal disease in Danish children aged <2 years: a population-based cohort study," *Clin Infect Dis,* vol. 46, no. 8, pp. 1165-71, 2008.

Supporting information

S1 Text. Supplementary Appendix


Cohort Vaccination
Noncolonized
Vaccination
Vaccinated Noncolonized
Colonization
Carriage clearance
Colonization
Carriage clearance
Co-colonization
Colonized
Vaccination
Vaccinated Colonized
Co-colonization
Colonization
Carriage clearance
Colonization
Carriage clearance
Co-colonized
Vaccination
Vaccinated Co-colonized
Colonization
Carriage clearance
Colonization
Carriage clearance
Triple-colonized
Vaccination
Vaccinated Triple-colonized
Vaccination
Waned Vaccine
Disease progression
Disease progression
Waning
Disease progression
Pneumococcal Disease


PCV7
PCV13 non-PCV7 non-ST3
ST3
PCV15 non-PCV13
PPSV23
PCV20 non-PCV15
Unique V116 STs
NVT
0–1
2–4
5–17
IPD incidence (cases per 100'000)
Date (y)


PCV7
PCV13 non-PCV7 non-ST3
ST3
PCV15 non-PCV13
PPSV23
PCV20 non-PCV15
Unique V116 STs
NVT
18–49
50–64
65+
IPD incidence (cases per 100'000)
Date (y)


PCV13-type IPD in <2
PCV15 non-PCV13-type IPD in <2
Non-PCV15-type IPD in <2
Overall incidence in <2
Overall incidence in 2-4
Overall incidence in 65+
Incidence (cases per 100,000)
2020
2030
2040
2050
PCV15 in children <2
PCV13 in children <2


Data
Strategy PCV13
Strategy PCV15
2000 (steady state)
2019 (final data point)
2030 (year−10 projection)
0–1
2–4
5–17
18–49
50–64
65+
Other STs
PCV20 non−PCV15
PCV15 non−PCV13
ST3
PCV13 non−PCV7 non−ST3
PCV7